Technical Analysis for GTHX - G1 Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
47.64 | 0.21% | 0.10 |
GTHX closed up 2.15 percent on Friday, July 20, 2018, on 43 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Aug 8
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| See historical GTHX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jul 20 | Bollinger Band Squeeze | Range Contraction | 0.21% |
| Jul 20 | Overbought Stochastic | Strength | 0.21% |
| Jul 19 | Bollinger Band Squeeze | Range Contraction | 2.36% |
| Jul 19 | Stochastic Reached Overbought | Strength | 2.36% |
| Jul 19 | Inside Day | Range Contraction | 2.36% |
| Jul 19 | Overbought Stochastic | Strength | 2.36% |
| Jul 18 | Crossed Above 50 DMA | Bullish | 0.21% |
| Jul 18 | MACD Bullish Signal Line Cross | Bullish | 0.21% |
| Jul 18 | Bollinger Band Squeeze | Range Contraction | 0.21% |
| Jul 18 | Up 3 Days in a Row | Strength | 0.21% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-08-08
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more GTHX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 52.76 |
| 52 Week Low | 12.04 |
| Average Volume | 350,589 |
| 200-Day Moving Average | 31.5669 |
| 50-Day Moving Average | 45.7204 |
| 20-Day Moving Average | 45.486 |
| 10-Day Moving Average | 45.805 |
| Average True Range | 2.5717 |
| ADX | 12.58 |
| +DI | 19.5532 |
| -DI | 18.5995 |
| Chandelier Exit (Long, 3 ATRs ) | 42.2849 |
| Chandelier Exit (Short, 3 ATRs ) | 49.0051 |
| Upper Bollinger Band | 48.7855 |
| Lower Bollinger Band | 42.1865 |
| Percent B (%b) | 0.81 |
| BandWidth | 14.507761 |
| MACD Line | 0.4543 |
| MACD Signal Line | 0.2778 |
| MACD Histogram | 0.1765 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.34 Billion |
| Num Shares | 28.3 Million |
| EPS | -11.02 |
| Price-to-Earnings (P/E) Ratio | -4.31 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 4.87 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 50.74 | ||||
| Resistance 3 (R3) | 50.66 | 49.53 | 50.20 | ||
| Resistance 2 (R2) | 49.53 | 48.71 | 49.56 | 50.02 | |
| Resistance 1 (R1) | 48.53 | 48.21 | 49.03 | 48.61 | 49.85 |
| Pivot Point | 47.40 | 47.40 | 47.65 | 47.43 | 47.40 |
| Support 1 (S1) | 46.40 | 46.58 | 46.90 | 46.48 | 45.23 |
| Support 2 (S2) | 45.27 | 46.08 | 45.30 | 45.06 | |
| Support 3 (S3) | 44.27 | 45.27 | 44.88 | ||
| Support 4 (S4) | 44.35 |
